• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Khosla Ventures Acquisition Co. Announces Redemption of Public Shares and Subsequent Dissolution

    12/4/23 5:38:00 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KVSA alert in real time by email

    MENLO PARK, Calif., Dec. 4, 2023 /PRNewswire/ -- Khosla Ventures Acquisition Co. (the "Company") (NASDAQ:KVSA) today announced that it will redeem all of its outstanding shares of Class A common stock that were issued in its initial public offering and not previously redeemed (the "public shares"), effective as of the close of business on December 11, 2023, as the Company will not consummate an initial business combination on or prior to December 8, 2023.

    Pursuant to the Amended and Restated Certificate of Incorporation, if the Company does not complete its initial business combination by December 8, 2023, then the Company will: (i) cease all operations except for the purpose of winding up, (ii) promptly redeem the public shares within ten business days thereafter, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Company's trust account including interest earned on the funds held in the trust account (less taxes payable and up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public shareholders' rights as shareholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) thereafter, subject to the approval of the Company's remaining shareholders and its board of directors, dissolve and liquidate, subject in each case to the Company's obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.

    The per-share redemption price for the public shares will be approximately $10.75.

    The public shares will cease trading as of the close of business on December 11, 2023. As of the close of business on December 11, 2023, the public shares will be deemed cancelled and will represent only the right to receive the redemption amount.

    The redemption amount will be payable to the holders of the public shares upon delivery of their shares. Beneficial owners of public shares held in "street name," however, will not need to take any action in order to receive the redemption amount.

    The Company expects that the Nasdaq Stock Exchange will file a Form 25 with the United States Securities and Exchange Commission (the "Commission") to delist the Company's securities. The Company thereafter expects to file a Form 15 with the Commission to terminate the registration of its securities under the Securities Exchange Act of 1934, as amended.

    Cautionary Note Regarding Forward-Looking Statements

    Certain information contained in this press release may be deemed to constitute forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts for future events, including, without limitation, the redemption of the Company's public shares and the Company's subsequent dissolution and liquidation and its delisting from the Nasdaq Stock Exchange and its termination of registration with the Commission. These statements may be preceded by, followed by or include the words "may," "might," "will," "will likely result," "should," "estimate," "plan," "project," "forecast," "intend," "expect," "anticipate," "believe," "seek," "continue," "target" or similar expressions. Such statements are subject to certain risks and uncertainties that could cause our actual results in the future to differ materially from the Company's historical results and those presently anticipated or projected. The Company wishes to caution investors not to place undue reliance on any such forward-looking statements. Any forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date. The Company assumes no obligation to update forward-looking statements except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect to those or other forward-looking statements.

    Cision View original content:https://www.prnewswire.com/news-releases/khosla-ventures-acquisition-co-announces-redemption-of-public-shares-and-subsequent-dissolution-302005173.html

    SOURCE Khosla Ventures Acquisition Co.

    Get the next $KVSA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KVSA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KVSA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Khosla Ventures Acquisition Co. Announces Redemption of Public Shares and Subsequent Dissolution

    MENLO PARK, Calif., Dec. 4, 2023 /PRNewswire/ -- Khosla Ventures Acquisition Co. (the "Company") (NASDAQ:KVSA) today announced that it will redeem all of its outstanding shares of Class A common stock that were issued in its initial public offering and not previously redeemed (the "public shares"), effective as of the close of business on December 11, 2023, as the Company will not consummate an initial business combination on or prior to December 8, 2023. Pursuant to the Amended and Restated Certificate of Incorporation, if the Company does not complete its initial business combination by December 8, 2023, then the Company will: (i) cease all operations except for the purpose of winding up,

    12/4/23 5:38:00 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Valo Health and Khosla Ventures Acquisition Co. Mutually Agree to Terminate Business Combination Agreement

    BOSTON and MENLO PARK, Calif., Nov. 15, 2021 /PRNewswire/ -- Valo Health, LLC ("Valo"), the technology company using human-centric data and artificial intelligence (AI) powered computation to transform the drug discovery and development process and Khosla Ventures Acquisition Co. (NASDAQ:KVSA) ("KVSA"), a special purpose acquisition company sponsored by affiliates of Khosla Ventures, LLC, announced today that both companies have mutually agreed to terminate their previously announced agreement and plan of merger (the "Business Combination Agreement"), effective immediately. Both parties decided to terminate the Business Combination based on current market conditions, particularly in the biot

    11/15/21 5:40:00 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Valo Health and Khosla Ventures Acquisition Co. Announce Additional PIPE Commitments

    BOSTON and MENLO PARK, Calif., Nov. 9, 2021 /PRNewswire/ -- Valo Health, LLC ("Valo"), the technology company using human-centric data and artificial intelligence (AI) powered computation to transform the drug discovery and development process, and Khosla Ventures Acquisition Co. (NASDAQ:KVSA) ("KVSA"), a special purpose acquisition company sponsored by an affiliate of Khosla Ventures, LLC ("Khosla Ventures"), today announced that the private placement of common stock ("PIPE") investment in connection with their previously announced business combination had expanded from $168.5M to over $200M exceeding initial targets.

    11/9/21 4:00:00 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KVSA
    SEC Filings

    View All

    SEC Form 15-12G filed by Khosla Ventures Acquisition Co.

    15-12G - Khosla Ventures Acquisition Co. (0001841873) (Filer)

    12/21/23 9:20:51 AM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Khosla Ventures Acquisition Co. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Khosla Ventures Acquisition Co. (0001841873) (Filer)

    12/12/23 5:25:01 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 25-NSE filed by Khosla Ventures Acquisition Co.

    25-NSE - Khosla Ventures Acquisition Co. (0001841873) (Subject)

    12/11/23 5:05:42 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KVSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Khosla Ventures Acquisition Co. (Amendment)

    SC 13G/A - Khosla Ventures Acquisition Co. (0001841873) (Subject)

    2/14/24 4:55:28 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Khosla Ventures Acquisition Co. (Amendment)

    SC 13G/A - Khosla Ventures Acquisition Co. (0001841873) (Subject)

    2/12/24 12:56:18 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Khosla Ventures Acquisition Co.

    SC 13G - Khosla Ventures Acquisition Co. (0001841873) (Subject)

    2/14/23 4:18:34 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KVSA
    Financials

    Live finance-specific insights

    View All

    Khosla Ventures Acquisition Co. Announces Planned Transfer of Listing to NYSE in Connection with its Proposed Business Combination with Valo Health

    BOSTON and MENLO PARK, Calif., Oct. 28, 2021 /PRNewswire/ -- Khosla Ventures Acquisition Co. (NASDAQ:KVSA) ("KVSA"), a special purpose acquisition company sponsored by an affiliate of Khosla Ventures, LLC ("Khosla Ventures"), today announced that it will voluntarily transfer the listing of its Class A common stock, par value $0.0001 per share ("Class A Common Stock"), from the Nasdaq Capital Market ("Nasdaq") to the New York Stock Exchange ("NYSE") in connection with, and following the closing of, the previously announced business combination (the "Business Combination") with Valo Health, Inc. ("Valo"), the wholly owned subsidiary of Valo Health, LLC ("Valo Health"). The shares of Class A Co

    10/28/21 7:13:00 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care